IXCHIQ is developed by Centre Hospitalier Universitaire de la Réunion.

What development phase is IXCHIQ in?

IXCHIQ is FDA-approved (marketed).

What are the side effects of IXCHIQ?

Common side effects include Headache, Fatigue, Myalgia, Arthralgia, Fever, Nausea.

Last reviewed 2026-04-20 · How we verify

IXCHIQ

Centre Hospitalier Universitaire de la Réunion · FDA-approved active Biologic Quality 6/100

At a glance

Generic name	IXCHIQ
Sponsor	Centre Hospitalier Universitaire de la Réunion
Modality	Biologic
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

Headache
Fatigue
Myalgia
Arthralgia
Fever
Nausea
Tenderness (injection site)

Key clinical trials

Real-world Effectiveness, Safety and Immunogenicity of Chikungunya Vaccination in Populations at Risk of Severe or Complicated Forms: Prospective Study in La Réunion (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

IXCHIQ CI brief — competitive landscape report
IXCHIQ updates RSS · CI watch RSS
Centre Hospitalier Universitaire de la Réunion portfolio CI